Home
Mail
News
Sport
Finance
Celebrity
Style
Weather
Mobile
Messenger
Movies
More
Yahoo
Mail
News
Market Data
Crypto
Bank of England
Money Matters
Property
Top Stocks
Work & Management
Industry News
Brexit
My Portfolio
My Screeners
Watchlists
Videos
UK markets close in 7 hours 18 minutes
FTSE 100
8,384.25
-39.95
(-0.47%)
FTSE 250
20,786.74
-86.59
(-0.41%)
AIM
806.89
-3.05
(-0.38%)
GBP/EUR
1.1698
+0.0000
(+0.00%)
GBP/USD
1.2707
+0.0000
(+0.00%)
Bitcoin GBP
55,844.75
+3,160.12
(+6.00%)
Travel
UK’s best city break revealed
This 'lively' and 'buzzing' city beat London and Cardiff in a new ranking
Neumora Therapeutics, Inc. (NMRA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.69
+0.02
(+0.21%)
At close: 04:00PM EDT
9.69
0.00
(0.00%)
After hours:
04:00PM EDT
Summary
Chart
Conversations
Statistics
Historical data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income statement
Balance sheet
Cash flow
Annual
Quarterly
Income statement
All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
222,895
206,623
104,749
212,776
87,126
Selling general and administrative
50,109
45,475
31,121
24,547
8,392
Total operating expenses
273,004
252,098
135,870
237,323
95,518
Operating income or loss
-273,004
-252,098
-135,870
-237,323
-95,518
Total other income/expenses net
-156
-170
405
11
-3,754
Income before tax
-253,753
-235,657
-130,904
-237,312
-99,272
Income tax expense
-
268
0
-
-
Income from continuing operations
-254,021
-235,925
-130,904
-237,312
-99,272
Net income
-254,021
-235,925
-130,904
-237,312
-99,272
Net income available to common shareholders
-254,021
-235,925
-130,904
-237,312
-99,272
Basic EPS
-1.02
-3.63
-4.81
-1.56
-0.65
Diluted EPS
-1.02
-3.63
-4.81
-1.56
-0.65
Basic average shares
151,949
65,021
27,207
151,949
151,949
Diluted average shares
151,949
65,021
151,949
151,949
151,949
Data disclaimer
Help
Suggestions
Terms
and
Privacy Policy
Privacy dashboard
About our ads
© 2024 Yahoo. All rights reserved.